Irbesartan/Hydrochlorothiazid Micro Labs (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing the hormone from causing blood vessels to narrow and from stimulating aldosterone release. This results in vasodilation and reduced fluid retention, which together lower systemic vascular resistance and help control blood pressure.

The appropriate dose of Irbesartan/Hydrochlorothiazide is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and other individual factors. Dosage adjustments may be needed for renal function, age, or concomitant medications.

Safety of Irbesartan/Hydrochlorothiazide in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents, the Irbesartan/Hydrochlorothiazide combination offers dual action—vascular relaxation from the ARB and diuresis from the thiazide—allowing more effective blood‑pressure control in patients who need both mechanisms. It may reduce the need for multiple separate pills, improving adherence.

The product should be stored at room temperature, below 25 °C, in its original packaging. It must be kept away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Irbesartan/Hydrochlorothiazide is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe allergic reactions (anaphylaxis), acute kidney injury, and significant hypotension. Patients should be monitored for signs of these events, and therapy should be discontinued immediately if any serious adverse reaction is suspected.

Individuals with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation should avoid the product. It is also contraindicated in patients with severe renal impairment, anuria, or those taking prohibited drug combinations such as other ARBs, ACE inhibitors, or potassium‑sparing diuretics.